Seeking Alpha

Isis Pharma (ISIS) -4.8% to $12.41 despite Stifel Nicolaus raising its price target for the...

Isis Pharma (ISIS) -4.8% to $12.41 despite Stifel Nicolaus raising its price target for the company to $17 from $11 and maintaining its Buy rating. Stifel made the move after meeting with Isis' management and said investors underestimate the company's pipeline. Shares have been rising since April, although in a fairly volatile fashion.
Comments (1)
  • KValinoti
    , contributor
    Comments (8) | Send Message
     
    They just achieved "orphan drug" status on yet another drug in their pipeline! Anyone who thinks ISIS is all about Kynamro, is ignorant.
    30 Jul 2012, 11:09 AM Reply Like
DJIA (DIA) S&P 500 (SPY)